News and events

ExeVir’s COVID-19 antibody candidate neutralizes coronavirus Variants of Concern

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has generated data on its COVID-19 antibody ...

July 13, 2021

ExeVir Announces Close of $50 million/ EUR42 million Series A Financing

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, today announces that it has closed its Series A financing raising ...

March 16, 2021

ExeVir Bio Announces New Publication from VIB Scientists Showing Potent and Broad Neutralizing Activity and Infection Protection against SARS-COV-2 and related coronaviruses

ExeVir, which is developing single domain antibody therapies providing broad protection against viral infections, announces publication in BioRxiv of a paper by VIB scientists showing, ...

March 9, 2021

ExeVir Bio Appoints Michel Kazatchkine and Stef Heylen to the Board of Directors

ExeVir, which is developing nanobody therapies providing broad protection against viral infections, including a lead candidate for coronaviruses, today announced that Michel Kazatchkine and Stef ...

November 3, 2020

ExeVir Bio to Accelerate Development of New Treatment Conferring Broad Protection Against Covid-19

ExeVir Bio announces today a first closing of a EUR23 million Series A financing led by Fund+, with the participation of VIB, UCB Ventures, the ...

July 28, 2020